6.42 USD
↘ 0.70 (9.83%)AT CLOSE (11:59 AM EDT)
Ernexa Therapeutics Inc. Common Stock
ERNANASDAQ • USD
6.50
↗ 0.08 (1.17%)
POST MARKET (AS OF 07:59 PM EDT)
Post Market
AS OF 07:59 PM EDT
6.50
↗ 0.08 (1.17%)
Market: CLOSED
Ernexa Therapeutics Inc. Common Stock (ERNA) is currently trading at $6.53. Technicals currently rate "Sell" while our fundamental analysis reads "Neutral". This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Valuation metrics suggest ERNA is trading at a discount to its peers, earning an "Attractively Valued" rating.
Technical & fundamental data as of Jul 17, 2026.
Open?$6.95
High?$7.21
Low?$6.42
Prev. Close?$7.12
Volume?117.8K
Avg. Volume?929.5K
VWAP?$6.83
Rel. Volume?0.13x
Bid / Ask
Bid?$5.46 × 100
Ask?$7.51 × 100
Spread?$2.05
Midpoint?$6.48
Valuation & Ratios
Market Cap?8.3M
Shares Out?1.2M
Float?13.7M
Float %?46.9%
P/E Ratio?N/A
P/B Ratio?1.21
EPS?-$9.78
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.
Themes
Address
1035 CAMBRIDGE STREET
CAMBRIDGE, MA 02141
Phone: (617) 798-6700
CAMBRIDGE, MA 02141
Phone: (617) 798-6700
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?0
Momentum?77
Short Sent.?100
Piotroski F-Score?0/9Weak
Altman Z-Score?-35.06Distress
Confidence?40%Low
Short InterestLow
Short % of Float?0.22%Low
Short Interest?29.4K
Days to Cover?1.0
Free Float13.7M
Avg Daily Volume69.3K
Settlement Date2026-06-30
Financial Health
Current Ratio?2.89Strong
Quick Ratio?2.89Strong
Cash Ratio?2.65Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score100/100
P/E?N/A▾
P/B?1.21CHEAP▾
Peers100
S&P93
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?0.1CHEAP▾
Peers100
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-166.3%WEAK▾
S&P3
ROA?-108.2%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-7255000
Enterprise Value?$-872709
Fundamentals ratios updated end of day